This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary IGF-1R Therapeutic Antibody Development
Background of IGF-1R
The overexpression or aberrant activation of IGF-1R is closely associated with tumor development, invasion, and metastasis in many types of cancer. Targeting IGF-1R with veterinary therapeutic antibodies may hold potential for the treatment of companion animal cancers. BioVenic offers a one-stop service for the development of veterinary IGF-1R therapeutic antibodies, covering everything from antibody preparation to characterization, encompassing both upstream and downstream aspects of antibody development. We are committed to assisting in providing new treatment solutions for companion animal cancers.
Background of IGF-1R
| Full Name | Insulin-like growth factor 1 receptor |
|---|---|
| Aliases | CD221, Igf1r, IGFIR, IGFR, JTK13. |
| Target Profile | The Insulin-like Growth Factor 1 Receptor (IGF-1R) is a transmembrane tyrosine kinase receptor that binds insulin-like growth factors with high affinity. It is extensively involved in the processes of cell growth, differentiation, survival, and metabolic regulation. The IGF-1 receptor is constituted by two α subunits and two β subunits. The α subunits are located externally on the cell, and responsible for ligand binding, while the β subunits span the cell membrane and are responsible for intracellular signal transduction upon ligand stimulation. |
MoA of IGF-1R
When IGF-1 or IGF-2 binds to IGF-1R, it initiates a conformational change in the receptor, leading to the phosphorylation of downstream substrates such as IRS1, IRS2, and Shc. This activation triggers multiple downstream signaling pathways, such as PI3K-AKT and MAPK-ERK, which are crucial for cell growth, proliferation, and apoptosis.
Fig.1 Schematic diagram of IGF-1R pathways.1
Application in Veterinary Therapeutics
Overexpression of IGF-1R is common and associated with poor prognosis in canine osteosarcoma, mammary tumors, melanomas, and insulinomas. Therapeutic strategies targeting IGF-1R include the use of antibodies to inhibit its activity. By blocking the interaction between IGF-1R and its ligands (such as IGF-1 and IGF-2), the binding and receptor activation are prevented. There is potential to inhibit tumor cell growth and survival, as well as induce apoptosis of tumor cells.
Veterinary IGF-1R Therapeutic Antibody Development Services
Considering the high frequency of IGF-1R overexpression in certain types of companion animal cancers, therapies targeting the IGF-1R pathway offer a new treatment option for animals with these cancer types. BioVenic specializes in providing services for developing IGF-1R therapeutic antibodies with our diverse technological platform. Our services aim to assist in creating veterinary therapeutic antibodies that specifically bind and modulate the activity of IGF-1R, providing safer and more effective treatment options for animals. Additionally, our services include antibody characterization and engineering design to ensure optimal therapeutic efficacy of the developed veterinary IGF-1R therapeutic antibodies.
For more information on developing veterinary IGF-1R therapeutic antibodies, please visit the link below.
Why Choose Us?
We offer tailored service solutions based on your specific requirements, covering the entire spectrum from antibody screening, and preparation, to engineering design for your selection.
Our diverse platform specializes in developing veterinary therapeutic antibodies, offering a variety of options including traditional and cutting-edge technologies like hybridoma, single B-cell sorting, and phage display techniques.
We adhere to stringent quality control standards to ensure the safety and efficacy of the final antibody samples, supporting research endeavors.
In various companion animal cancers, the IGF-1R gene plays a pivotal role, especially in cancers associated with IGF-1R overexpression, such as canine mammary cancer. BioVenic's veterinary IGF-1R therapeutic antibody development services encompass not just complete preparation but also precise optimization to ensure the high affinity and specificity of the antibodies. If you are considering developing IGF-1R-targeted antibodies for animal cancer treatment, please contact us to assist in developing effective veterinary IGF-1R therapeutic antibodies!
References
- Sandhu, Romeil, et al. "An analytical approach for insulin-like growth factor receptor 1 and mammalian target of rapamycin blockades in ewing sarcoma." arXiv preprint arXiv:1509.03642 (2015).
- Maniscalco, Lorella, et al. "Increased expression of insulin-like growth factor-1 receptor is correlated with worse survival in canine appendicular osteosarcoma." The Veterinary Journal 205.2 (2015): 272-280.